NAD+ Injection: Administration Routes in the Research Literature
Published clinical and preclinical research on NAD+ injection — IV infusion, subcutaneous, and intramuscular routes. Doses, tolerability data, and protocol comparison from the peer-reviewed literature.
What Is an NAD+ Injection?
An NAD+ injection delivers nicotinamide adenine dinucleotide directly into tissue — subcutaneously (under the skin) or intramuscularly (into muscle) — or into the bloodstream via intravenous infusion. The mechanism is to bypass the oral bioavailability limitation: intact NAD+ is rapidly hydrolyzed in the gastrointestinal tract, so parenteral administration is the only way to achieve high systemic NAD+ concentrations quickly.[10][11]
Published pharmacokinetic data confirm the rationale. During a 6-hour intravenous infusion of 750 mg NAD+ in healthy males (infusion rate approximately 2 mg/min in normal saline), plasma NAD+ and metabolites — NMN, AMP, and nicotinamide — rose substantially and were detectable in urine, establishing the first pharmacokinetic characterization of IV NAD+ administration in humans.[10]
Two parenteral routes have clinical evidence: intravenous infusion (two published human studies) and subcutaneous injection (predominantly rodent data; limited human clinical use). Intramuscular use is described in some clinical protocols but lacks published PK data in humans.[10]
NAD+ IV Therapy vs Subcutaneous Injection
The key difference between IV infusion and subcutaneous injection is delivery rate and resulting plasma concentration profile. IV infusion delivers the full dose directly into the bloodstream, achieving near-100% bioavailability and immediate plasma NAD+ elevation. Subcutaneous injection delivers into interstitial tissue, with slower absorption into systemic circulation — producing a flatter, more sustained concentration curve than IV at equivalent doses.
In preclinical rodent studies used to model cognitive endpoints, five administration routes were characterized: intraperitoneal (most common in rodent research), subcutaneous, oral/gavage, intravenous, and intracerebroventricular. A single subcutaneous injection of NMN at 1.2 g/kg proved ineffective in cognitive endpoint models — suggesting that duration and route interact, and that repeated parenteral dosing over 7–28 days was required to see cognitive effects in the preclinical models studied.[26]
For human IV therapy vs subcutaneous injection, no published head-to-head comparison exists. IV data is available from the Grant et al. 2019 pilot study and the Reyna et al. 2026 retrospective tolerability comparison. Subcutaneous human data remains largely anecdotal in the published record.
Safety Profile of NAD+ IV Therapy in Published Studies
Published infusion trials report a consistent adverse-event pattern: nausea, chest tightness, elevated heart rate, and burning or pressure at the infusion site. These events are rate-dependent — they occur more often with faster infusion — and resolve when infusion speed is slowed or the infusion concludes. No serious adverse events were reported in either published IV NAD+ human study.[10][11]
The Reyna et al. 2026 retrospective real-world tolerability study compared IV NAD+ (500 mg) to IV NR (500 mg) over 4 consecutive days. IV NAD+ required a mean infusion time of 97 minutes and was associated with moderate-to-severe GI symptoms, elevated heart rate, and chest pressure. IV NR required only 37 minutes on average and caused only mild tingling with no moderate or severe events. All symptoms resolved upon infusion completion in both groups.[11]
The practical implication from Reyna et al. is that slower infusion rates are required for IV NAD+ to manage tolerability, while IV NR appears to tolerate faster administration. Both remain in the pilot/retrospective category — larger prospective tolerability studies have not been published.
IV NAD+ vs Oral: Bioavailability Comparison
IV infusion delivers NAD+ directly into the bloodstream with near-100% bioavailability. Oral NAD+ itself is poorly absorbed as an intact molecule — gut extracellular enzymes (CD38, CD73, ENPP1) degrade most of the intact NAD+ before it can enter systemic circulation, making oral precursors (NMN, NR) the preferred oral strategy in most published studies.[10]
The Grant et al. 2019 pilot study established the first human pharmacokinetic profile for IV NAD+: 750 mg infused over 6 hours elevated plasma NAD+ throughout the infusion, with multiple metabolites appearing in plasma and urine, including NMN, AMP, and nicotinamide.[10] Oral precursors at equivalent milligram doses produce substantially lower peak plasma NAD+, but are the only route studied over multi-week periods with consistent blood NAD+ elevation confirmed.[1][2][3]
| Route | Bioavailability | Peak Plasma | Duration of Effect | Human Data |
|---|---|---|---|---|
| IV | Near 100% | High (immediate) | Infusion period | 2 pilot studies |
| Oral NMN | Good (Slc12a8 transporter) | 15 min post-dose | Daily dosing maintains | 8+ RCTs |
| Oral NR | Good (nucleoside transporter) | Variable | Daily dosing maintains | 10+ RCTs |
| Oral NAD+ | Very low (GI hydrolysis) | Metabolites only | N/A | Not studied directly |
What Does the Research Say About NAD+ Injection Efficacy?
Published human trials show injections raise blood NAD+ levels more reliably than oral dosing in terms of peak plasma concentration and speed of onset. Whether elevated NAD+ translates to the studied outcomes — energy, cognition, longevity markers — depends on the endpoint, and results vary across trials.[10][11][26]
The most informative injectable data in humans comes from the IV infusion studies: Grant et al. 2019 (single-session pharmacokinetics, 750 mg IV) and Reyna et al. 2026 (real-world 4-day protocol comparison of IV NAD+ vs IV NR, 500 mg each). The preclinical data from Qader et al. 2025 — a systematic review of NAD+ precursors in rodent cognitive models — shows that repeated parenteral dosing over 7–28 days is required for cognitive endpoints, while single-dose parenteral administration was not effective.[26] No published human RCT has used injectable NAD+ as the primary study arm over a multi-week period.
NAD+ Injection Frequency in Research Protocols
Published protocols vary widely. The Reyna et al. 2026 real-world study administered IV NAD+ (500 mg) over 4 consecutive days — a loading-protocol design.[11] Some IV clinical series in the broader literature administer daily infusions for 4–10 days (loading), then monthly maintenance; the specific protocols differ by clinical setting and endpoint.
For subcutaneous injection, the published preclinical rodent research used frequencies ranging from daily to twice weekly, typically over 7–28-day study periods.[26] No published human RCT has established a validated subcutaneous NAD+ frequency protocol with a controlled endpoint.
Frequency data from the oral studies is more robust: daily dosing for 8–12 weeks is the standard protocol in published NMN and NR trials, producing sustained blood NAD+ elevation confirmed at weeks 4, 8, and 12.[2][3]
Compounded NAD+ vs Oral Formulations: Why Reconstitution Matters
Injectable NAD+ formulations used in research are pharmaceutical-grade lyophilized powders reconstituted in sterile water or normal saline — not the same as oral supplement capsule contents. Oral supplement capsules contain excipients, binding agents, and fillers formulated for gastrointestinal tolerance, not for parenteral administration. These excipients introduce improper pH and contamination risks that are not studied or characterized for injection.
The Grant et al. 2019 pharmacokinetic study used pharmaceutical-grade IV-formulated NAD+ under controlled clinical conditions.[10] All published parenteral NAD+ research uses similarly validated formulations. The stability profile, sterility requirements, and formulation specifications of an injectable NAD+ preparation are categorically different from those of an oral supplement.
NAD+ Infusion Protocols in Clinical Research
The published human infusion data covers two protocols. Grant et al. 2019 used a single 6-hour infusion of 750 mg NAD+ at approximately 2 mg/min in normal saline in healthy males — establishing the pharmacokinetic baseline.[10] Reyna et al. 2026 used a 4-consecutive-day protocol at 500 mg per day for both IV NAD+ and IV NR, with mean infusion times of 97 minutes (IV NAD+) and 37 minutes (IV NR) respectively.[11]
The Reyna et al. 2026 data provides the most operationally useful comparison for infusion protocol design: IV NR achieved equivalent or superior NAD+ exposure with better tolerability and shorter infusion time in the real-world clinical setting studied. However, this is retrospective and observational data — a prospective controlled comparison has not been published. No regulatory body has approved a specific NAD+ infusion protocol for any indication.